1. Home
  2. MTVA vs DUO Comparison

MTVA vs DUO Comparison

Compare MTVA & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTVA
  • DUO
  • Stock Information
  • Founded
  • MTVA 2014
  • DUO 2011
  • Country
  • MTVA United States
  • DUO China
  • Employees
  • MTVA N/A
  • DUO N/A
  • Industry
  • MTVA
  • DUO Real Estate
  • Sector
  • MTVA
  • DUO Finance
  • Exchange
  • MTVA NYSE
  • DUO Nasdaq
  • Market Cap
  • MTVA 18.9M
  • DUO 17.1M
  • IPO Year
  • MTVA N/A
  • DUO 2019
  • Fundamental
  • Price
  • MTVA $1.95
  • DUO $0.61
  • Analyst Decision
  • MTVA Strong Buy
  • DUO
  • Analyst Count
  • MTVA 1
  • DUO 0
  • Target Price
  • MTVA $12.00
  • DUO N/A
  • AVG Volume (30 Days)
  • MTVA 337.7K
  • DUO 2.0M
  • Earning Date
  • MTVA 11-07-2024
  • DUO 08-30-2024
  • Dividend Yield
  • MTVA N/A
  • DUO N/A
  • EPS Growth
  • MTVA N/A
  • DUO N/A
  • EPS
  • MTVA N/A
  • DUO N/A
  • Revenue
  • MTVA N/A
  • DUO $37,352,654.00
  • Revenue This Year
  • MTVA N/A
  • DUO N/A
  • Revenue Next Year
  • MTVA N/A
  • DUO N/A
  • P/E Ratio
  • MTVA N/A
  • DUO N/A
  • Revenue Growth
  • MTVA N/A
  • DUO 6.61
  • 52 Week Low
  • MTVA $1.51
  • DUO $0.32
  • 52 Week High
  • MTVA $6.75
  • DUO $4.67
  • Technical
  • Relative Strength Index (RSI)
  • MTVA N/A
  • DUO 46.04
  • Support Level
  • MTVA N/A
  • DUO $0.53
  • Resistance Level
  • MTVA N/A
  • DUO $0.62
  • Average True Range (ATR)
  • MTVA 0.00
  • DUO 0.05
  • MACD
  • MTVA 0.00
  • DUO 0.00
  • Stochastic Oscillator
  • MTVA 0.00
  • DUO 43.82

About MTVA METAVIA INC

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

Share on Social Networks: